share_log

Altimmune | 4: Statement of changes in beneficial ownership of securities-Director Drutz David

SEC ·  Aug 21 06:08
Summary by Futu AI
On August 19, 2024, Dr. David Drutz, associated with Altimmune, Inc. [ALT], engaged in multiple transactions involving the company's common stock. Dr. Drutz acquired a total of 41,750 shares through the exercise of derivative securities at prices ranging from $2.50 to $2.60. Subsequently, Dr. Drutz sold a total of 16,011 shares on the open market at prices between $6.88 and $6.93, resulting in a total market value of $110,547.03 for the disposed shares. After these transactions, Dr. Drutz's beneficial ownership in Altimmune stands at 55,524 shares.
On August 19, 2024, Dr. David Drutz, associated with Altimmune, Inc. [ALT], engaged in multiple transactions involving the company's common stock. Dr. Drutz acquired a total of 41,750 shares through the exercise of derivative securities at prices ranging from $2.50 to $2.60. Subsequently, Dr. Drutz sold a total of 16,011 shares on the open market at prices between $6.88 and $6.93, resulting in a total market value of $110,547.03 for the disposed shares. After these transactions, Dr. Drutz's beneficial ownership in Altimmune stands at 55,524 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.